In the non-TNBC group, a HR indicating notably lower breast cancer mortality was seen for the VEGFR2 positive patients, HR = 0.04 (95% CI 0.001–3.3), but this result was not significant (P = 0.16). This evidence concerns the gene KDR and breast carcinoma.